Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
Linear Formula:
H2O
CAS Number:
Molecular Weight:
18.02
NACRES:
NA.83
PubChem Substance ID:
UNSPSC Code:
12191602
EC Number:
231-791-2
MDL number:
Beilstein/REAXYS Number:
2050024
Bp:
100 °C (lit.)
Product Name
E-Toxate™ Water, endotoxin, free
form
liquid
dilution
(for analytical testing)
impurities
endotoxin, free
refractive index
n20/D 1.34 (lit.)
bp
100 °C (lit.)
mp
0 °C (lit.)
density
1.000 g/mL at 3.98 °C (lit.)
application(s)
detection
compatibility
reagent for E-Toxate™
SMILES string
O
InChI
1S/H2O/h1H2
InChI key
XLYOFNOQVPJJNP-UHFFFAOYSA-N
Legal Information
E-Toxate is a trademark of Sigma-Aldrich Co. LLC
Still not finding the right product?
Explore all of our products under E-Toxate™ Water
Storage Class
12 - Non Combustible Liquids
ppe
Eyeshields, Gloves
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Related Content
Instructions
Philippe Robert et al.
Investigative radiology, 50(8), 473-480 (2015-06-25)
To prospectively compare in healthy rats the effect of multiple injections of macrocyclic (gadoterate meglumine) and linear (gadodiamide) gadolinium-based contrast agents (GBCAs) on T1-weighted signal intensity in the deep cerebellar nuclei (DCN), including the dentate nucleus. Healthy rats (n =
Mary A Rodgers et al.
The Journal of experimental medicine, 211(7), 1333-1347 (2014-06-25)
Linear ubiquitination is a newly discovered posttranslational modification that is currently restricted to a small number of known protein substrates. The linear ubiquitination assembly complex (LUBAC), consisting of HOIL-1L, HOIP, and Sharpin, has been reported to activate NF-κB-mediated transcription in
Yasushi Itoh et al.
PLoS pathogens, 10(6), e1004192-e1004192 (2014-06-20)
Highly pathogenic avian influenza (HPAI) viruses of the H5N1 subtype often cause severe pneumonia and multiple organ failure in humans, with reported case fatality rates of more than 60%. To develop a clinical antibody therapy, we generated a human-mouse chimeric